The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.
Alessandra Gennari
No relevant relationships to disclose
Dino Amadori
No relevant relationships to disclose
Etienne Brain
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Nadia Harbeck
No relevant relationships to disclose
Matteo Puntoni
No relevant relationships to disclose
Rachel Wuerstlein
No relevant relationships to disclose
Oriana Nanni
No relevant relationships to disclose
Eva Muñoz-Couselo
No relevant relationships to disclose
Giovanni Paganelli
No relevant relationships to disclose
Maribel Lopera Sierra
Employment or Leadership Position - Advanced Accelerator Applications
Federica Matteucci
No relevant relationships to disclose
Arnoldo Piccardo
No relevant relationships to disclose
Paolo Bruzzi
No relevant relationships to disclose